Latest news

ABAC AbYlink Acteon afabicin (Debio 1450) afabicin (Debio 1450) ABSSSI afabicin (Debio 1450) Bone & joint infections Award BC Platforms Biocartis Campus après-demain CARB-X Carbonex CDiff Challenge Debiopharm-Inartis Clinical Trials Coorpacademy CPP cyclosporin A Debio 0123 Debio 0228 Debio 025 Debio 0507 Debio 0513 Debio 0517 Debio 0614 (istaroxime) Debio 0615 Debio 0617 Debio 0719 Debio 0824 Debio 0826 Debio 0827 Debio 0928 Debio 0929 Debio 0930 Debio 0931 Debio 0932 NSCLS Debio 0932 RCC Debio 1036 Debio 1124 Debio 1124 SCLC Debio 1141 Debio 1142 Debio 1143 Debio 1143 Head & neck cancer Debio 1143 NSCLC Debio 1143 Ovarian cancer Debio 1143 selected solid tumors Debio 1143 with pembrolizumab Debio 1144 Debio 1347 Debio 1348 Debio 1449 Debio 1453 Debio 1454 Debio 1454M Debio 1460 Debio 1561 Debio 1562 Debio 8206 SC Debio 8609 Sanvar Debio 9902 - ZT-1 Debiopharm Academy Debiopharm Chair in Family Philanthropy Debiopharm Life Sciences Award Debiovision Degraducer Diagnoplex EPFL EPI-hNE4 FibroTrap fuze Galiena Capital genepoc Groupe Bertrand H3 Pharma Haut-Lac HES-SO Huperzine-A IDEAL Immunexpress InnoCentive JCA-Mauvernay Award Kaiku Health KeyLemon little green house Moapar Multilink Muscular Dystrophy naratuximab emtansine (Debio 1562) NeoVacs Novadiscovery nucleai Oncology Chair oncomfort Oxaliplatin paper.li PLGA Prix Debiopharm/Valais revogene Skiioo Spinomix Swiss Biotech Association Téléthon Tremelimumab Triptorelin xevinapant

June 16, 2021

Debiopharm and Ubix Therapeutics launch research to develop a new anti-cancer modality – antibody degraducer® conjugates

June 14, 2021

Debiopharm’s CD37 antibody drug conjugate shows promising phase II results for the treatment of B-cell malignancies

March 1, 2021

Debiopharm Grants a Worldwide Exclusive License to Merck for the Development and Commercialization of Xevinapant

February 25, 2021

Debiopharm and Genome & Company Join Forces to Create New Highly Specific Therapies For Cancer Patients

September 17, 2020

Debiopharm to Present Late Breaking Head & Neck Cancer Abstract at the 2020 European Society Of Medical Oncology Congress

August 26, 2020

Debiopharm’s New Generation Radionuclide Therapy Advances Into Clinical Research In The Fight Against Lung Cancer

June 10, 2020

Debiopharm’s novel microbiome remodeling program licensed to Takeda for the treatment of gastrointestinal disorders

March 25, 2020

Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy

March 5, 2020

Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor